Temozolomide (TMZ) is a standard agent used in the treatment of various types of cancers, including lung carcinoma, but TMZ resistance is common and accounts for many treatment failures. We investigated miRNA-487b-5p (miR-487b-5p) was highly expressed in A549 and H1299 cells which acquired TMZ resistance. Suppression of miR-487b-5p had overt effects on cellular proliferation and migration in the presence of TMZ. On the other hand, knockdown of miR-487b-5p resulted in increased survival and moderate tumor growth in vivo. In addition, the decreased cellular proliferation following miR-487b-5p suppression was linked to enhanced autophagy, evident by drastically increased levels of LC3-II, BECLIN1, and LAMP2 when miR-487b-5p was knocked down. Further analysis revealed that LAMP2 might be the target gene of miR-487b-5p. In conclusion, our study suggested that miR-487b-5p may be a potential biomarker of acquired TMZ resistance in lung cancer cells, and miR-487b-5p inhibition can be further explored as a chemotherapy target in the treatment of TMZ-resistant lung carcinoma.
Get full access to this article
View all access options for this article.
References
1.
AlavanjaM.C. (2002). Biologic damage resulting from exposure to tobacco smoke and from radon: implication for preventive interventions. Oncogene, 21, 7365–7375.
2.
BetelD., WilsonM., GabowA., MarksD.S., and SanderC. (2008). The microRNA.org resource: targets and expression. Nucleic Acids Res, 36, D149–D153.
3.
BilelloK.S., MurinS., and MatthayR.A. (2002). Epidemiology, etiology, and prevention of lung cancer. Clin Chest Med, 23, 1–25.
4.
BonciD., CoppolaV., MusumeciM., AddarioA., GiuffridaR., MemeoL., et al. (2008). The miR-15a-miR-16-1 cluster controls prostate cancer by targeting multiple oncogenic activities. Nat Med, 14, 1271–1277.
5.
BottoniA., PiccinD., TagliatiF., LuchinA., ZatelliM.C., and degli UbertiE.C. (2005). miR-15a and miR-16-1 down-regulation in pituitary adenomas. J Cell Physiol, 204, 280–285.
6.
CalinG.A., DumitruC.D., ShimizuM., BichiR., ZupoS., NochE., et al. (2002). Frequent deletions and down-regulation of micro-RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci U S A, 99, 15524–15529.
7.
Centers for Disease Control and Prevention. (2002). Recent trends in mortality rates for four major cancers, by sex and race/ethnicity—United States, 1990–1998. MMWR Morb Mortal Wkly Rep, 51, 49–53.
8.
DansonS.J., and MiddletonM.R. (2001). Temozolomide: a novel oral alkylating agent. Expert Rev Anticancer Ther, 1, 13–19.
9.
EnrightA.J., JohnB., GaulU., TuschlT., SanderC., and MarksD.S. (2003). MicroRNA targets in Drosophila. Genome Biol, 5, R1.
10.
Gomez-GutierrezJ.G., NitzJ., SharmaR., WechmanS.L., RiedingerE., Martinez-JaramilloE., et al. (2016). Combined therapy of oncolytic adenovirus and temozolomide enhances lung cancer virotherapy in vitro and in vivo. Virology, 487, 249–259.
11.
GunnJ.M., ClarkM.G., KnowlesS.E., HopgoodM.F., and BallardF.J. (1977). Reduced rates of proteolysis in transformed cells. Nature, 266, 58–60.
12.
ItoH., DaidoS., KanzawaT., KondoS., and KondoY. (2005). Radiation-induced autophagy is associated with LC3 and its inhibition sensitizes malignant glioma cells. Int J Oncol, 26, 1401–1410.
13.
JohnsonS.M., GrosshansH., ShingaraJ., ByromM., JavisR., ChengA., et al. (2005). RAS is regulated by the let-7 microRNA family. Cell, 120, 635–647.
14.
KanzawaT., GermanoI.M., KomataT., ItoH., KondoY., and KondoS. (2004). Role of autophagy in temozolomide-induced cytotoxicity for malignant glioma cells. Cell Death Differ, 11, 448–457.
15.
KirkegaardK., TaylorM.P., and JacksonW.T. (2004). Cellular autophagy: surrender, avoidance and subversion by microorganisms. Nat Rev Microbiol, 2, 301–314.
16.
KisenG.O., TessitoreL., CostelliP., GordonP.B., SchwarzeP.E., BaccinoF.M., et al. (1993). Reduced autophagic activity in primary rat hepatocellular carcinoma and ascites hepatoma cells. Carcinogenesis, 14, 2501–2505.
17.
LiL., and LiJ. (2015). [Lentivirus-mediated shRNA silencing of LAMP2A inhibits the proliferation of multiple myeloma cells]. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi, 31, 605–608, 14.
18.
LinC.J., LeeC.C., ShihY.L., LinC.H., WangS.H., ChenT.H., et al. (2012). Inhibition of mitochondria- and endoplasmic reticulum stress-mediated autophagy augments temozolomide-induced apoptosis in glioma cells. PLoS One, 7, e38706.
19.
MidthunD.E., and JettJ.R. (1997). Chemotherapy for advanced lung cancer. When to expect a response. Postgrad Med, 101, 187–188, 91–92, 94 passim.
20.
MooreL.M., and ZhangW. (2010). Targeting miR-21 in glioma: a small RNA with big potential. Expert Opin Ther Targets, 14, 1247–1257.
21.
NicolosoM.S., SpizzoR., ShimizuM., RossiS., and CalinG.A. (2009). MicroRNAs—the micro steering wheel of tumour metastases. Nat Rev Cancer, 9, 293–302.
22.
OtsukaH., and MoskowitzM. (1978). Differences in the rates of protein degradation in untrasformed and transformed cell lines. Exp Cell Res, 112, 127–135.
23.
PaglinS., HollisterT., DeloheryT., HackettN., McMahillM., SphicasE., et al. (2001). A novel response of cancer cells to radiation involves autophagy and formation of acidic vesicles. Cancer Res, 61, 439–444.
24.
Rodriguez-RochaH., Gomez-GutierrezJ.G., Garcia-GarciaA., RaoX.M., ChenL., McMastersK.M., et al. (2011). Adenoviruses induce autophagy to promote virus replication and oncolysis. Virology, 416, 9–15.
25.
RoutA.K., StrubM.P., PiszczekG., and TjandraN. (2014). Structure of transmembrane domain of lysosome-associated membrane protein type 2a (LAMP-2A) reveals key features for substrate specificity in chaperone-mediated autophagy. J Biol Chem, 289, 35111–35123.
26.
SchwarzeP.E., and SeglenP.O. (1985). Reduced autophagic activity, improved protein balance and enhanced in vitro survival of hepatocytes isolated from carcinogen-treated rats. Exp Cell Res, 157, 15–28.
27.
SmalheiserN.R., LugliG., RizaviH.S., ZhangH., TorvikV.I., PandeyG.N., et al. (2011). MicroRNA expression in rat brain exposed to repeated inescapable shock: differential alterations in learned helplessness vs. non-learned helplessness. Int J Neuropsychopharmacol, 14, 1315–1325.
28.
StuppR., HegiM.E., MasonW.P., van den BentM.J., TaphoornM.J., JanzerR.C., et al. (2009). Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol, 10, 459–466.
29.
StuppR., MasonW.P., van den BentM.J., WellerM., FisherB., TaphoornM.J., et al. (2005). Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med, 352, 987–996.
30.
TakamizawaJ., KonishiH., YanagisawaK., TomidaS., OsadaH., EndohH., et al. (2004). Reduced expression of the let-7 microRNAs in human lung cancers in association with shortened postoperative survival. Cancer Res, 64, 3753–3756.
31.
TentoriL., and GrazianiG. (2009). Recent approaches to improve the antitumor efficacy of temozolomide. Curr Med Chem, 16, 245–257.
32.
WaltonL., McNeillR., StevensW., MurrayM., LewisC., AitkenD., et al. (2013). Patient perceptions of barriers to the early diagnosis of lung cancer and advice for health service improvement. Fam Pract, 30, 436–444.
33.
ZhangX.D., WuJ.J., GillespieS., BorrowJ., and HerseyP. (2006). Human melanoma cells selected for resistance to apoptosis by prolonged exposure to tumor necrosis factor-related apoptosis-inducing ligand are more vulnerable to necrotic cell death induced by cisplatin. Clin Cancer Res, 12, 1355–1364.
34.
ZhouY., RuckerE.B.III, and ZhouB.P. (2015). Autophagy regulation in the development and treatment of breast cancer. Acta Biochim Biophys Sin (Shanghai), 48, 60–74.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
